Evidence map›Paper›PMID 34477360›Full record

ArticleACS chemical neuroscience2021

High Throughput Screening Cascade To Identify Human Aspartate

Ondřej Nešuta, Ajit G Thomas, Jesse Alt, Niyada Hin, Anna Neužilová, Shunyou Long, Takashi Tsukamoto, Camilo Rojas, Huijun Wei, Barbara S Slusher

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Discovery ofACS medicinal chemistry letters · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ondřej NešutaJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.
Ajit G ThomasJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.
Jesse AltJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.
Niyada HinJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.
Anna NeužilováJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.
Shunyou LongChemBioCORE, High Throughput Screening Facility, Johns Hopkins University, 733 N. Broadway, Baltimore, Maryland 21205, United States.
Takashi TsukamotoJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.ORCID 0000-0002-0216-7520
Camilo RojasJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.
Huijun WeiJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.ORCID 0000-0003-1961-614X
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins School of Medicine, 855 N. Wolfe Street, Baltimore, Maryland 21205, United States.ORCID 0000-0001-9814-4157
Johns Hopkins University · US

Funding

High throughput screen for discovery of N-acetyltransferase 8 Like (NAT8L) inhibitorsR61NS119659 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH, TSUKAMOTO, TAKASHI · 2021 to 2022
$813k
Development of NAT8L inhibitors for the Treatment of Canavan DiseaseR61NS136652 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH, TSUKAMOTO, TAKASHI · 2024 to 2025
$790k
High Throughput Screen for Discovery of N-Acetyltransferase 8 Like (NAT8L) InhibitorsR33NS119659 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH, TSUKAMOTO, TAKASHI · 2023 to 2023
$409k
NINDS NIH HHS R33 NS119659NINDS NIH HHS R61 NS119659NINDS NIH HHS R61 NS136652
6 · The paper itself

Abstract

Canavan disease (CD) is a progressive, fatal neurological disorder that begins in infancy resulting from a mutation in aspartoacyclase (ASPA), an enzyme that catalyzes the deacetylation of

Indexed as

Canavan DiseaseAcetyltransferasesAnimalsAspartic AcidBrainEscherichia coliHigh-Throughput Screening AssaysHumansMiceAcetyltransferasesaspartate N-acetyltransferaseAspartic Acidacetyl-CoAaspartate N-aceyltransferase (ANAT)aspartoacyclase (ASPA)Canavan diseasel-aspartateN-acetyl aspartate (NAA)N-acetyltransferase-8-like (NAT8L)

Identifiers

PMID34477360
PMCPMC11833907
OpenAlexW3197565319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.